TRCT
MIST icon

Tower Research Capital (TRC)’s Milestone Pharmaceuticals MIST Stock Holding History

Tower Research Capital (TRC)’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9K Buy
9,147
+167
+2% +$292 ﹤0.01% 3868
2025
Q4 		$18.1K Buy
+8,980
New +$19.3K ﹤0.01% 3174
2023
Q3 		– Sell
-172
Closed -$490 – 6124
2023
Q2 		$490 Buy
172
+73
+74% +$275 ﹤0.01% 5620
2023
Q1 		$0 Sell
99
-1,148
-92% -$4.2K ﹤0.01% 6107
2022
Q4 		$5K Buy
+1,247
New +$6.56K ﹤0.01% 4883
2022
Q1 		– Sell
-555
Closed -$4K – 6375
2021
Q4 		$4K Buy
555
+408
+278% +$2.44K ﹤0.01% 5325
2021
Q3 		$1K Sell
147
-1,419
-91% -$8K ﹤0.01% 5502
2021
Q2 		$9K Buy
+1,566
New +$8.88K ﹤0.01% 4441
2021
Q1 		– Sell
-1,096
Closed -$7K – 5583
2020
Q4 		$7K Buy
1,096
+180
+20% +$1.21K ﹤0.01% 4498
2020
Q3 		$7K Sell
916
-1,507
-62% -$10.8K ﹤0.01% 4240
2020
Q2 		$9K Buy
+2,423
New +$7.8K ﹤0.01% 4059
2020
Q1 		– Sell
-142
Closed -$2K – 3556
2019
Q4 		$2K Sell
142
-7
-5% -$124 ﹤0.01% 3076
2019
Q3 		$3K Sell
149
-1,728
-92% -$34K ﹤0.01% 3569
2019
Q2 		$51K Buy
+1,877
New +$38.7K ﹤0.01% 1562

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Tower Research Capital (TRC)'s MIST Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Milestone Pharmaceuticals (MIST) stake by 1.9% in Q1 2026, buying an estimated $292 and bringing the position to 9,147 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3868.

Tower Research Capital (TRC) first reported a position in MIST in Q2 2019 and has held it in 14 quarters since. The position peaked at $51K in Q2 2019. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Tower Research Capital (TRC) held 9,147 shares of Milestone Pharmaceuticals worth $10.9K as of Q1 2026.
  • Tower Research Capital (TRC) bought 167 Milestone Pharmaceuticals shares in Q1 2026, an estimated $292.
  • Milestone Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3868 holding.
  • Tower Research Capital (TRC) first reported a position in Milestone Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Milestone Pharmaceuticals position peaked at $51K in Q2 2019.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.